Title | Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy [electronic resource] / edited by Stephen B. Howell |
---|---|
Imprint | Boston, MA : Springer US : Imprint: Springer, 1991 |
Connect to | http://dx.doi.org/10.1007/978-1-4899-0738-7 |
Descript | XII, 546 p. online resource |
Synthetic Chemistry and Biochemistry -- Platinum DNA Chemistry -- New Insights About the Interaction of Cisplatinum with Intracellular Components -- Modelling Platinum โ DNA Interactions -- From the Modelization of DNA Platination to the Conception of New Drugs -- cis-Diammineplatinum (II) Complexes Tethered to DNA-Affinic Ligands: Antitumor Activity and DNA-binding Properties -- Complexes of Peptides and Related Molecules with Diammineplatinum (II) as Models for Platinum-Protein Interactions -- Reactivity of DNA and cis-Diamminedichloroplatinum (II) in the Presence of Intercalating Agents -- Structurally Novel Platinum Antitumor Compounds -- Synthesis and Reactions of a New Class of Orally Active Platinum (IV) Antitumor Complexes -- Pt-DNA Interactions: Oligonucleotide Models -- New Approaches to the Design of Platinum Antitumor Agents -- Developmental Approach to Prepare New Types of Antitumor Platinum Complexes with Dual Function -- Synthesis and Antitumor Activity of Some Novel Platinum(II) Organoamides and Organometallics -- Biochemical and Molecular Pharmacology -- Role of Membrane Ion Transport in Cisplatin Accumulation -- Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum (II) and Other Antitumor Agents by Inhibitors of Enzymes Involved in Growth Factor Signal-Transduction -- Signal Transduction Pathway Regulation of DDP Sensitivity -- The Role of Platinum-DNA Lesions in the Inhibition of DNA Replication -- Activation of a Genetic Program for Cell Death -- Molecular Aspects of Repair and Mutagenesis of cis-Platin-Induced Lesions -- Isolation of a Gene Associated with Resistance to Cisplatin -- Repair of Damaged DNA In Vitro by Extracts from Human Cell Lines -- Gene Specific Damage and Repair of Platinum Adducts and Crosslinks -- A Protein from Mammalian Cells That Recognizes Piatinated DNA -- Sensitization of Resistant Human Tumor Cells to Cisplatin or Carboplatin by Inhibitors of DNA Excision Repair -- Carrier Ligand Effects in Platinum-resistant Cell Lines -- Immunocytochemical Analysis of Platinum-DNA Adducts -- Strategies for Increasing the Efficacy of and Overcoming Resistance to Platinum Complexes In Vivo -- The Role of c-fos Oncogenes in Cisplatin Resistance -- Metallothioneins and Cisplatin Resistance -- A New Membrane Protein Associated with Resistance to cis-Platinum and Methotrexate -- Toxicology and Clinical Pharmacology of New Drugs -- Pharmacokinetics of Carboplatin in Children and the Development of a Paediatric Dose Equation -- Clinical Studies with Cisplatin Analogues, 254-S, DWA2114R and NK121 -- Clinical and Pharmacokinetic Studies on the New Platinum Complex, Zeniplatin (CL286, 558) -- Oxalatoplatinum (I-OHP): Experimental and Clinical Studies -- Pharmacologic Studies with New Liposome-Entrapped Cisplatin Derivatives -- Ammine/Amine Platinum IV Dicarboxylates: A Novel Class of Complexes Which Circumvent Intrinsic Cisplatin Resistance -- Clinical Trials -- Dose Intensity Analysis May Help Resolve Issues in Chemotherapy with Platinum Compounds -- Cisplatin Dose-intensity in Testicular Cancer Treatment: Analysis of a Randomized Clinical Trial -- Phase I/II Study to Further Escalate the Dose of Carboplatin in Combination with GM-CSF in the Treatment of Refractory Ovarian Cancer -- High Dose Carboplatin with Peripheral Blood Stem Cell and Growth Factor Support -- Pharmacologic, Pre-clinical and Clinical Investigations of the Cisplatin/Taxol Combination -- Phase I Trials with Ormaplatin (Tetraplatin) -- Intraperitoneal Cisplatin and Carboplatin in the Management of Ovarian Cancer -- Radiotherapy Combined with Daily or Weekly cis-Diamminedichloroplatinum (II) in Inoperable Non-metastasized Non-small Cell Lung Cancer: A Toxicity Report of the Randomized Phase III Study of the EORTC Lung Cancer Cooperative and Radiotherapy Cooperative Groups -- Optimizing Dose-Intensity: Combining Carboplatin with Cisplatin -- High Dose Cisplatin: Modulation of Toxicity -- Probenecid and Diethyldithiocarbamate as Modifiers of Cisplatin Toxicity -- ORG 2766 in the Prevention of Cisplatin Neuropathy -- WR-2721 (Ethyol): Reduction in Toxicity of Anticancer Therapy without Loss of Efficacy -- High-Dose Cisplatin with Glutathione Protection in Gynecologic Malignancies -- Improved Efficacy of โTwo-route Chemotherapyโ Using Cisplatin and its Antidote, Sodium Thiosulfate in Combination with Angiotensin II